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INTRODUCTION
The initial issue of Current Alzheimer Research (CAR) was first published in 2004, a year 
marked by the glories of the Athens Summer Olympics as well as the destruction of the 
Asian Tsunami [1]. Over the last decade, scientific knowledge has moved rapidly forward 
across numerous disciplines, marked by the discovery of the potential for water and life on 
Mars [2,3], the generation of the first induced pluripotent stem cells [4], the creation of the 
first cell controlled by a synthetic genome [5], and genome editing [6]. In the realm of 
dementia-now, beyond the centennial of the first presentation by Alois Alzheimer on the 
disease that bears his name [7], important changes too have occurred in the past decade. 
Whereas the exact prevalence of dementia remains unknown, it is crystal clear that dementia 
is a common, devastating and costly condition amongst the elderly. The WHO 2012 Report 
“Dementia: a public health priority” [8] estimates that 35.6 million people suffered with 
dementia worldwide in 2010. An estimated incidence that is much higher than that 
approximated in 2004 (18 million people [9]), and this value has undoubtedly grown still 
more in 2014.
Total new cases of dementia each year worldwide are predicted as 7.7 million or one every 
four seconds, with the greatest number of new cases occurring in developing countries. 
Particularly afflicted are the elderly in China, India, and their south Asian neighbors whose 
health care systems, like those of North America and European nations, are unimaginably 
strained. Alzheimer’s disease (AD) is the most frequent cause of dementia impacting some 
5.5 million people in the USA. What have we learned over the past decade and, more 
importantly, how have scientific discoveries translated to impact the care of patients 
suffering from this disease?
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To date, extraordinary progress has been achieved in elucidating the molecular events 
underpinning the neuropathology and cellular dysfunction associated with AD. Additionally, 
significant new knowledge has also been gained through the identification of genetic 
mutations associated with AD predisposition as well as AD resilience. Much progress has 
been made to establish broader national and international collaborations. In addition, public/
private partnerships have generated greater cooperation and alliances between academia, the 
pharmaceutical industry and funding organizations. However, no efficacious treatments have 
yet been found to delay or stop the progression of AD. Therefore, we currently remain at a 
cross-road in the study and treatment of AD. We now need to select which of the many 
potential road maps will lead towards the hopeful translation of our ever increasing basic 
science knowledge into clinically effective interventions for AD [10, 11]. At the same time, 
the persistent universal financial crisis is placing an ever-increasing strain on AD research 
limiting our options of following multiple routes to find a correct one.
In the face of these pressures – indeed, stimulated by these pressures – remarkable scientific 
advances have and can continue to be made. Breakthroughs, epitomized by those in brain 
imaging, target elucidation and drug screening [12–15], are opening the door to 
unprecedented opportunities for the advancement of basic research into human development. 
Thus far, advances in the study of neuropsychiatric disorders and AD, in particular, have too 
often been lost in translation [16] in that these fields of research represent areas of high drug 
attrition [17], but they also are of great opportunity [18]. Advancement in AD research can 
be achieved by linking new target evaluation and characterization to disease progression and 
drug discovery in order to provide a mechanism for preclinical optimization with clinical 
translation and appraisal in human disease. While this pursuit is often long and tortuous, it 
requires continuous interactions between scientists from numerous backgrounds.
Over the past decade, Current Alzheimer Research has provided an important instrument to 
support this essential crosstalk both between as well as within disciplines. All too often a 
completely new pair of eyes, frequently from outside the field rather than from within, can 
provide the impetus to follow a new pathway or see an important association whose 
relevance others may have missed. Current Alzheimer Research intersects a broad spectrum 
of many disciplines including cellular and molecular biology, pharmacology, medicinal 
chemistry/drug development and discovery, molecular diagnostics, brain imaging, 
neurogenetics, and neurology. Far more than many other longer established scientific 
journals, Current Alzheimer Research provides a forum to understand these diverse research 
approaches in relation to clinical aspects of AD and associated disorders by being inclusive 
of scientists from different fields. Equally important, Current Alzheimer Research likewise 
readily accommodates for those who may not necessarily be within the main stream of AD 
research but who can provide a critical reality check [19] as to whether or not chosen 
directions may be fruitful or fruitless. Thereby these researchers can assess the status of the 
“Emperor’s new clothes” [20].
Since its inception in 2004, Current Alzheimer Research has been listed in PubMed/
MEDLINE as well as other notable indexing services, such as BIOBASE, EMBASE, 
NURSING EMCare, Chemical Abstracts, Current Contents, Genomics, JournalSeek and 
PsycINFO databases. The scope of our indexing is essential to disseminate new research 
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findings to other investigators within and across fields. Additionally, Current Alzheimer 
Research continues to receive coverage in Thomson Scientific products and services: 
BIOSIS Previews, Journal Citation Reports/Science Edition®, Neuroscience Citation Index® 
and Science Citation Index Expanded (also known as SciSearch®).
As a consequence of the relevance and scientific quality of the papers on one side and the 
indexing, review and timeliness provided by the publisher, Bentham Science, on the other, 
Current Alzheimer Research is one of the top 35 journals among 193 Clinical Neurology 
journals, and has consistently maintained a high impact factor and ranking (the current 
impact factor is 3.67 with a five-year impact factor of 4.20). Beyond this number and 
ranking, the quality of citations of the journal’s articles speak volumes of the journal itself. 
For example, several articles published in Current Alzheimer Research have been referenced 
in other reputable journals, including JAMA, Nature Medicine (plus other Nature publishing 
group’s journals), N. Eng. J. Med., Neuron, J. Neuroscience, Proc. Natl. Acad. Sci. USA, 
Science and Sci. Transl. Med.
Bentham Science continues to supply free online Abstracts of each article and the full text of 
Editorials on the journal’s website (http://benthamscience.com/journal/index.php?
journalID=car#top). Moreover, each first issue of the year’s journal volume is now made 
available for free open access viewing of all published articles. Bentham Science launched a 
new website in January 2014 with many new attractive functionalities. The publisher is fully 
compliant with article deposit requirements of the National Institutes of Health (NIH), USA. 
Based on the feedback from authors and readers, the journal has started handling all its 
submission and editorial processes by the ScholarOne system, thereby making the 
publication experience more efficient and user-friendly.
Notably, the Editorial Board for Current Alzheimer Research has been revamped recently 
with the inclusion of several experts and reviewers in the field, including two Nobel 
Laureates. We all are benefitted by their advice and expertise, and are thankful for their time 
and service to the journal and, in turn, to the AD field of research.
Besides publishing standard review and research articles, the journal also publishes full or 
mini ‘Thematic Issues’. These ‘Thematic Issues’ are focused on contemporary topics that 
represent recent developments in the field, and these issues are guest edited by eminent 
scientists. The number of expert contributions varies from 8 to 10 articles for a Full-
Thematic Issue to 5 articles for a Mini-Thematic Issue. Such thematic issues are widely 
read, and usually receive higher citations compared to the regular journal issues that are 
published. During the last year alone, the journal successfully published several separate 
theme-based ‘hot topic’ issues. These provide the latest exciting information on high profile 
subjects, in addition to the excellent articles covering an extensive range of topics in our 
regular issues.
The articles in the 11th volume of Current Alzheimer Research cover a wide breadth of 
recent research in AD. The research topics include several disease-modifying and 
interventional strategies as well as brain imaging, immunotherapy, neuroinflammation, and 
neuropathology. In addition, this volume will continue to publish the theme-based issues 
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written by a group of experts in the field. Indeed, several interesting issues are lined up for 
publication this year. These timely and exciting contributions are key to the success and 
future progress of the AD field, and should be well worth reading. We also continue to 
follow the original mission of the journal [1] and the recently proposed vision [21].
Last year, a special session on neurodegenerative diseases was held with eminent scholars to 
commemorate the achievement of Current Alzheimer Research at the “Drug Discovery & 
Therapy World Congress 2013” (DDTWC 2013) in Boston, USA. Likewise, we are also 
planning to highlight the advances in AD this year and to celebrate the 10th year anniversary 
of Current Alzheimer Research at the DDTWC 2014 in Boston from June 16–19, 2014. It is 
our distinct pleasure to invite you to join the celebration of your achievements riding on the 
“CAR”, as Current Alzheimer Research journal is affectionately called the most reliable and 
dynamic vehicle to report and disseminate AD research. Our scientific journey with the 
CAR has been uninterrupted, productive and all-season-serving through the bumpy roads of 
the 2004 Summer Olympics to the memorable 2014 Winter Olympics. We hope and are 
planning for the continuation of this success with your support and contributions.
On behalf of Bentham Science and the Editorial Board, we profoundly thank the authors, 
readers, and the neuroscience community for their advice, input and support. We express our 
sincere gratitude to the guest editors, reviewers and referees of manuscripts. Indeed, their 
combined efforts and insights have significantly enriched the quality of articles published in 
the journal. Finally, we are especially grateful to the staff of Bentham Science for their 
indefatigable effort and cooperation in creating the final shape of the journal.
As we focus on our mission and attempt to keep the engine of scientific discovery both 
running as well as moving in the correct direction – rather than, between us, generating 
inconsistent results [22,23], our goal should be to join the rank of one of the highly touted 
scientific discoveries of the year [24]. This goal will provide shared success between the 
authors and readers of Current Alzheimer Research that, hopefully, will be more 
successfully translated to and enjoyed by the public – particularly those suffering from AD 
and their care givers. Our hope is that Current Alzheimer Research will continue to 
contribute towards accelerating the progress of the AD research field, imparting the latest 
findings so that they can be rapidly acted upon. We always look forward to your comments 
and contributions. At this longed-for moment of the uninterrupted 11th anniversary of the 
journal’s inception, let us join in wishing a bright, creative and successful future for Current 
Alzheimer Research.
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